Edesa Biotech Inc. reported its financial results for the three months ended December 31, 2025. The company posted a net loss of USD 2.2 million, or USD 0.28 per common share, compared to a net loss of USD 1.6 million, or USD 0.48 per common share, for the same period in the previous year. Research and development expenses totaled USD 1.12 million, while general and administrative expenses were USD 1.22 million for the quarter. Total other income decreased to USD 0.1 million, primarily due to lower reimbursement funding from the Canadian government's Strategic Response Fund. As of December 31, 2025, Edesa Biotech had cash and cash equivalents of USD 12.1 million and working capital of USD 12.0 million. The company plans to participate in several upcoming industry events, including the Global Vitiligo Foundation Annual Scientific Symposium, BIO Europe Spring 2026, Respiratory Innovation Summit, and the American Thoracic Society 2026 International Conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edesa Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131620PRIMZONEFULLFEED9654186) on February 13, 2026, and is solely responsible for the information contained therein.